Immunotherapy for men on active surveillance?

So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …

Can a “new Dendreon” re-make Provenge?

At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …

Court clears acquisition of Dendreon by Valeant

After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.

Valeant to acquire assets of Dendreon

According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.

What is going to happen to Dendreon and Provenge?

According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Supply and demand — Dendreon accelerates development of manufacturing capacity for Provenge

The signals from Dendreon in September last year were that it would take the company until at least the end of 2011 to be able to “ramp up” to full manufacturing capacity for its prostate cancer immunotherapeutic agent, sipuleucel-T (Provenge), even if the FDA does approve this product in May or June of 2010 — which is what most people are currently expecting. … READ MORE …

The IMPACT trial results: Tuesday April 27, 2009

OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer. … READ MORE …

Provenge data results … for those who can’t get to the AUA meeting

Dendreon has previously announced that the results of the IMPACT trial will be presented at the annual meeting of the American Urological Association at approximately 2:20 pm on Tuesday, April 28. The company has now announced that, in addition, it will hold a webcast conference call at 4:30 pm CT (5:30 pm ET, 2:30 pm PT) the same day to present these data to people unable to attend the AUA annual meeting. … READ MORE …

FT says that another Provenge trial may still be needed

OK folks … please don’t shoot the messenger … I do not agree with the suggestions about the need for another trial in an article published today by the Financial Times. However, I would be a pretty poor reporter if I didn’t let you know this article is out there in a major international newspaper! I am not going to comment. Just read it for yourselves.

The full Provenge saga

For those who have come to the world of prostate cancer in the past 2 years or so, we recommend that, before you attempt to understand whatever happens on the day that Dendreon announces the results of the Phase III (IMPACT) trial of sipleucel-T, a.k.a. Provenge (expected some time this month), you read the well-constructed history of the clinical development of Provenge that has been posted to the Xconomy.com web site today. … READ MORE …

What’s new with Provenge?

The “New” Prostate Cancer InfoLink has seen a couple of statements from members of the financial community in the last few days that could mislead the unwary into believing that Dendreon’s investigational immunotherapeutic agent, sipuleucel-T (Provenge), has already demonstrated a statistically significant survival benefit in its most recent Phase III clinical trial (the IMPACT trial) … READ MORE …

The PM prostate cancer news: Wednesday, July 23

In additional news breaking today:

  • Dendreon Corp. is predicting interim results of the IMPACT study of Provenge in metastatic, androgen-independent prostate cancer by October 2008
  • The FDA has refused to approve an experimental, topical treatment for erectile dysfunction … MORE …